drugset / Trial / NCT05388656

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656

RandomizedCrossoverQuadruple-blindBasic science

Summary

Women in the menopause transition (perimenopause) experience substantial day-to-day variability in estradiol and have a 2-4-fold increase in major depression risk. About 40% of perimenopausal women are susceptible to the emergence of affective symptoms tied to changes in estradiol. Among the perimenopausal women with affective impairment, most report irritability, not "depression," is their primary source of impairment and distress. The purpose of this research is to determine the neurophysiologic basis of susceptibility to estradiol fluctuations and irritability symptoms in perimenopausal women.

Timeline

Start
2022-06-15
Primary completion
2024-12-17
Completion
2025-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 0.1 mg Other
Background Progesterone Other / unclassified 200 mg Oral

Indications